Hidroksiüre'nin Neden Olduğu Longitidunal Melanonişi

Öz

Hydroxyurea is a chemotherapeutic agent which is used in the management of myeloproliferative disorders. Mucocutaneous adverse effects and nail hyperpigmentation can be observed in long-term treatment. Cases of hydroxyurea-induced melanonychia develop predominantly in female patients and the most common pattern is longitudinal bands. Here we present a case of 65-year-old woman patient that has longitudinal melanonychia on the nails of the hands, observed at the eighteenth month of the treatment of hydroxyurea. By means of this case, it is aimed to be aware of the cutaneous side effects of hydroxyurea which is commonly used in myeloproliferative disorders

Anahtar Kelimeler

• Hydroxyurea; melanonychia, polycythemia vera

Hidroksiüre'nin Neden Olduğu Longitidunal Melanonişi

Öz

Hidroksiüre, miyeloproliferatif hastalıkların tedavisinde kullanılan sitostatik bir kemoterapotik bir ajandır. Uzun dönem tedavide mukokütanöz yan etkiler ve tırnak pigmentasyonu görülebilmektedir. Hidroxiürenin indüklediği melanonişi, en çok kadınlarda en sık olarak da longitidunal çizgilenme şeklinde görülür. Burada polisitemia rubra vera tanısıyla hidroksiüre kullanan, tedavisinin 18. ayında el parmak tırnaklarında longitudinal melanonişi ortaya çıkan 65 yaşında kadın hasta sunulmuştur. Bu vakadan hareketle, miyeloproliferatif hastalıklarda ve orak hücreli aneminin tedavisinde kullanımı gittikçe yaygınlaşan hidroksiürenin çok sayıdaki kutanöz yan etkilerinin farkında olunması amaçlanmıştır

Anahtar Kelimeler

• Hidroksiüre, melanonişi, polisitemi vera

Kaynakça

1. Ceulen RP, Frank J, Poblete-Gutiérrez P. Nail pigmentation due to hydroxycarbamide. Int J Dermatol 2007;46(3):13-5.
2. Joyner S, Lee D, Hay P, et al. Hydroxyurea-induced nail pigmentation in HIV patients. HIV Med 1999;1(1):40–2.
3. Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 2002;47(1):146–7.
4. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea. Arch Dermatol 1999; 135(7): 818–20.
5. Issaivanan M, Mitu PS, Chakrabarti M, et al. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol 2004; 21(2):124–7.
6. Oh ST, Lee DW, Lee JY, et al. Hydroxyurea-induced melanonychia concomitant with a dermatomyositis- like eruption. J Am Acad Dermatol 2003; 49 (2):339– 41.
7. Koley S, Choudhary S, Salodkar A. Melanonychia and skin hyperpigmentation with hydroxyurea therapy. Indian J Pharmacol 2010;42(1):60-1.
8. Utaş S, Kulluk P. A case of hydroxyurea- induced Dermatol 2010;49(4):469-70. melanonychia. Int J

9. Thomas L, Dalle S. Dermoscopy provides useful information for the management of melanonychia striata. Dermatol Ther 2007; 20(1): 3-10.
10. Murray NP, Tapia P, Porcell J, et al. Acquired mela- nonychia in chilean patients with essential throm- bocythemia treated with hydroxyurea: a report of 7 clinical cases and review of the literature. ISRN Der- matol 2013;2013:325246. doi: 10.1155/2013/325246. Epub 2013 Feb 7.
11. Thai KE, Young R, Sinclair RD. Nail apparatus melanoma. Australas J Dermatol 2001;42(2):71-81.
12. Wiechert A, Reinhard G, Tuting T, et al. Multiple skin cancers in a patient treated with hydroxyurea. Hautarzt 2009;60(8):651-4.